Scholar Rock/$SRRK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
- Ticker
- $SRRK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 289
- Headquarters
- Cambridge, United States
- Website
- www.scholarrock.com
Scholar Rock Metrics
BasicAdvanced
$5.5B
-
-$3.39
0.79
-
Price and volume
Market cap
$5.5B
Beta
0.79
52-week high
$61.76
52-week low
$36.78
Average daily volume
1.7M
Financial strength
Current ratio
5.409
Quick ratio
5.192
Long term debt to equity
1.169
Total debt to equity
1.203
Interest coverage (TTM)
-29.23%
Profitability
EBITDA (TTM)
-407.559
Gross margin (TTM)
-36,927.89%
Net profit margin (TTM)
-72,563.16%
Operating margin (TTM)
-71,732.28%
Management effectiveness
Return on assets (TTM)
-59.59%
Return on equity (TTM)
-199.97%
Valuation
Price to revenue (TTM)
9,644.844
Price to book
32.61
Price to tangible book (TTM)
32.61
Price to free cash flow (TTM)
-17.737
Free cash flow yield (TTM)
-5.64%
Free cash flow per share (TTM)
-2.542
Growth
Earnings per share change (TTM)
-4.82%
3-year earnings per share growth (CAGR)
6.29%
What the Analysts think about Scholar Rock
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Analyst projections of the future price of Scholar Rock stock.
Bulls say / Bears say
The FDA has approved Isembyld for adults and children aged two and older with SMA who are already on SMN2-targeted treatment. In the pivotal trial, the recommended dose improved motor-function scores by 2.2 points versus placebo, supporting a differentiated add-on treatment. (Scholar Rock, Inc.)
International growth could add to the US opportunity: Scholar Rock resubmitted its European application using the manufacturing site that supported US approval, with a European committee opinion expected in the first half of 2027. Japan’s regulator has agreed that no local clinical trial is needed before a planned filing. (Scholar Rock, Inc., Scholar Rock, Inc.)
The pipeline offers potential beyond the current SMA market: the company has started a Phase 2 apitegromab study in FSHD and is testing its separate myostatin drug SRK-439 in a Phase 1 study. Both are early-stage opportunities, rather than established sources of future sales. (Scholar Rock, Inc.)
Fractures are a notable safety concern: they occurred in 9% of patients on the approved dose versus 2% on placebo. The FDA also requires rapid reporting of fracture cases and a pregnancy safety study. (Scholar Rock, Inc., SEC)
Early sales may lag clinical interest because insurers must approve coverage and infusion centres need time to arrange treatment. Ahead of the first post-approval results, analysts expected only $1.43 million of third-quarter revenue, with reimbursement and billing delays potentially stretching the time to a first infusion beyond 60 days. (Investing.com)
Scholar Rock remains loss-making and may need more capital if sales do not ramp quickly: it reported a $215 million net loss in the first half of 2026 and said its cash would fund operations only into the second half of 2027 under its current plan. The company also said it would need additional capital to complete development and commercialisation of its programmes. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 9 Nov 2026.
Scholar Rock Financial Performance
Revenues and expenses
Scholar Rock Earnings Performance
Company profitability
Upcoming events
No upcoming events
Scholar Rock News
AllArticlesVideos
Funds containing Scholar Rock
Fund name | Fund size | $SRRK weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.3B | 0.36% |
iShares Nasdaq US Biotechnology£BTEK | $1.3B | 0.36% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.17% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.17% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $2.7B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


